What is CCRM Nordic?

CCRM Nordic is a not for profit organization established to address bottlenecks in the translation and commercialization of advanced therapy medicinal products (ATMPs) in Sweden, the Nordics and Europe.

CCRM Nordic is modelled on the highly successful CCRM in Canada and is legally separate to CCRM.

As a member of the Global CCRM network, CCRM Nordic is a partner to a leading edge industry consortium. CCRM Nordic is taking ATMPs from bench to bedside by treating and potentially curing some of the most devastating and costly diseases in the world today.

Meet the Team

Fredrik Wessberg
Chief Executive Officer

Jim Lund
Chief Business Development Officer (1st of Aug )

Board of Directors

The CCRM Nordic Board of Directors brings extensive knowledge and considerable expertise in the biotechnology and ATMP sectors. Their expertise will enable CCRM Nordic to achieve the next evolution of growth – to become the powerhouse that supports Sweden’s growing ATMP startup companies, research and investors who work tirelessly to translate and commercialize Swedish technologies.

Jan has many years of experience from large pharmaceutical companies and from smaller biotech companies. He has been active in several different areas of the pharmaceutical industry, ranging from the development of new drugs to the launch, sales, and marketing of established international brands. He also has a solid experience as a leader and has served as CEO of both private and public companies.

Born 1955. Senior Advisor at Patricia Industries AB since 2015, Lennart was previously Managing Director (Business Development, Operating and Financial Investments) at Investor AB (2006-2015). Prior to this he was Partner and Chief Executive Officer of Emerging Technologies ET AB. He is currently Board Member of Swedish Orphan Biovitrum AB and Hi3G Access AB; Deputy Chairman of Mölnlycke Health Care AB; and Chairman of Vectura AB. Lennart holds an MBA from the Stockholm School of Economics (1980).

Carl-Peter combines an international outlook with a strong Venture Capital network and Life Science expertise. He has extensive experience of international business projects across many industries, project partners, and financing strategies, and over 25 years of Venture Capital experience, including both direct and fund investments at national and international levels. He was previously the Head of Investor Relations and External Capital at Sahlgrenska Science Park, a central hub in the Life Science innovation system in West Sweden.

Catarina Flyborg is a seasoned executive with more than three decades of experience in the life sciences industry. She is driven by the potential of novel therapeutics to transform global healthcare.

Over the course of her career, she has held various management positions in sales, marketing, communications and product development at Cytiva.  These experiences have given her a 360 degree view of the infrastructure required to develop, manufacture, and commercialize therapies.

In her current role as Strategic Advisor Catarina provides insights into industry trends and high-level advice to the company’s leadership team.

Prior to that Catarina held the position as Vice President of the Cell & Gene Therapy franchise at Cytiva. In this role, she oversaw a team of more than 400 associates across R&D, manufacturing, commercial and marketing around the world. Teams that are developing the wing-to-wing solutions that are enabling research organizations, academic medical centers and biotechnology companies of all sizes to develop and manufacture life changing cell & gene therapies.

Since joining GE Healthcare in 2004, Catarina has led various teams including the Enterprise Solutions Group, Bioprocess Downstream Products and Cell & Gene Therapy Commercial and Marketing teams before being appointed to Vice President of Cell & Gene Therapy in 2018. Cell & Gene Therapy is one of three Business Units within Cytiva, which has 9000 employees globally, and an annual revenue of approx. $6B; Catarina is a member of the Cytiva’s management team.

Catarina was instrumental in building out the bioprocess product portfolio and oversaw the successful acquisition and integration of Xcellerex in the US (2012) and she has played pivotal roles in setting up manufacturing facilities in emerging markets. She earned her MSc in Biochemical Engineering from the Royal Institute of Technology in Stockholm and then began her career in the biotech industry working at Pharmacia Biotech in the product marketing group. She credits this experience with igniting her passion to further the convergence of science and technology and its impact on healthcare.

Jacqueline Barry is Chief Clinical Officer, responsible for Clinical Adoption activities, at Cell and Gene Therapy Catapult. In this role she leads the Access Strategy group (a multi-disciplinary team of Nonclinical, Regulatory, Health Economic); the CGT Catapult Edinburgh Centre and the coordination of the UK Advanced Therapy Treatment Centre Network.

She feels passionately about making advanced therapies available for patients and works closely industry partners and policy makers on the development of the ecosystems to support the adoption of these therapies.

Michael May is President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. CCRM is now seeking partners and financing for a commercial scale cell and gene therapy facility. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.

Michael sits on a number of boards and advisory committees including: the Ontario Life Sciences Council; the Board of Biologics Manufacturing Centre (BMC) Inc.; OmniaBio; ARM Foundation for Cell & Gene Medicine; and AgeX Corporation. He is the Chairman of ExCellThera Ltd.

Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.

Associate Professor, Dr Regina Fritsche-Danielson is accountable for research and early clinical development up to Ph3 in cardiovascular, renal and metabolic diseases. Regina received her PhD in Cardiovascular Physiology/Pharmacology at the University of Göteborg in 1993. After her postdoc, Regina was awarded a prestigious grant from the Swedish Natural Research Foundation (NFR). During her academic years Regina lead a research group and worked at the University of Göteborg, University of Ottawa, University of Queensland and University of Nevada. Regina joined AstraZeneca in 2001 and has held various leadership positions and led drug projects in discovery and development phases.

Regina is a steering committee member of several strategic research collaborations including Silence Therapeutics, Ionis Therapeutics, Procella therapeutics as well as the British Heart Foundation Centre for Research Excellence (CRE) Cambridge. She is also a board member of FluiCell AB, OligoNova and CCRM Nordic and she is an advisor for MRC Institute of Metabolic Science strategy University of Cambridge.